Over the last 7 days, the United States market has dropped 1.9%, yet it remains up by 30% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these promising earnings projections.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 244 stocks from our US High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Exact Sciences

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Exact Sciences Corporation focuses on cancer screening and diagnostic test products, operating both in the United States and internationally with a market cap of $12.90 billion.

Operations: The company generates revenue primarily from its biotechnology segment, which contributed $2.61 billion. It operates in the cancer screening and diagnostics industry, with a focus on innovative testing solutions.

Exact Sciences, a trailblazer in non-invasive cancer screening technologies, recently showcased its commitment to innovation with the FDA approval of Cologuard Plus, a next-generation colorectal cancer screening test. This development follows robust results from the BLUE-C study, indicating 95% sensitivity for detecting colorectal cancers. The company's strategic focus on research and development is evident as it allocated significant resources, ensuring that 11.0% of its revenue is reinvested into R&D activities. This investment supports not only product enhancement but also underpins future growth avenues in a market where early detection is key to improving patient outcomes. Moreover, Exact Sciences' recent presentations and FDA engagements suggest an ongoing effort to expand its diagnostic portfolio, aligning with industry shifts towards comprehensive screening solutions that promise higher accuracy and broader accessibility.

• Take a closer look at Exact Sciences' potential here in our health report.

• Gain insights into Exact Sciences' historical performance by reviewing our past performance report.

Iovance Biotherapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Iovance Biotherapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing cell therapies using autologous tumor infiltrating lymphocytes for treating metastatic melanoma and other solid tumor cancers in the United States, with a market cap of approximately $3.47 billion.

Operations: Iovance Biotherapeutics focuses on innovating, developing, and commercializing therapies using autologous tumor infiltrating lymphocytes (TIL) for cancer treatment, generating $32.77 million in revenue from this segment.

Iovance Biotherapeutics is making significant strides in the biotech sector, underscored by its impressive revenue growth forecast of 45.3% annually, outpacing the US market average of 8.9%. This growth trajectory is supported by a robust R&D commitment, with an expected sharp increase in earnings at a rate of 63.7% per year. Recent presentations at major healthcare conferences demonstrate the company's active engagement with industry advancements and potential market expansion. Despite current unprofitability and shareholder dilution over the past year, Iovance's aggressive R&D spending and strategic positioning hint at a promising shift towards profitability within three years, aligning with broader industry trends towards innovative therapeutic solutions.

• Get an in-depth perspective on Iovance Biotherapeutics' performance by reading our health report here.

• Assess Iovance Biotherapeutics' past performance with our detailed historical performance reports.

Apellis Pharmaceuticals

Simply Wall St Growth Rating: ★★★★★★

Overview: Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that specializes in discovering, developing, and commercializing therapeutic compounds targeting the complement system for autoimmune and inflammatory diseases, with a market cap of approximately $3.41 billion.

Operations: Apellis focuses on developing and commercializing proprietary therapeutics, generating approximately $628.79 million in revenue from these activities.

Apellis Pharmaceuticals has demonstrated a robust rebound in its financials, with a significant revenue jump to $196.83 million in Q3 2024 from $110.4 million the previous year, reflecting a growth rate of 78.3%. This surge is underpinned by promising clinical advancements, notably the VALIANT study results which showcased pegcetacoplan's efficacy in treating rare kidney diseases—a potential market differentiator given the high unmet medical need. The firm's strategic R&D focus is evident from its substantial reduction in net loss to $57.45 million from $140.24 million year-over-year and an aggressive investment in innovation, aligning with industry trends towards targeted therapies for complex conditions.

• Unlock comprehensive insights into our analysis of Apellis Pharmaceuticals stock in this health report.

• Gain insights into Apellis Pharmaceuticals' past trends and performance with our Past report.

Make It Happen

• Get an in-depth perspective on all 244 US High Growth Tech and AI Stocks by using our screener here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:EXAS NasdaqGM:IOVA and NasdaqGS:APLS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com